Skip to main content
Sona Nanotech Inc. logo

Sona Nanotech Inc. — Investor Relations & Filings

Ticker · SONA ISIN · CA83541C1059 CSE Professional, scientific and technical activities
Open in API
Filings indexed 424 across all filing types
Latest filing 2025-10-17 Regulatory Filings
Country CA Canada
Listing CSE SONA

About Sona Nanotech Inc.

https://www.sonanano.com/

Sona Nanotech Inc. is a life sciences company specializing in the development and commercialization of proprietary, uniquely biocompatible gold nanorod (GNR) technology. The primary therapeutic focus is Targeted Hyperthermia Therapy (THT), a photothermal cancer treatment utilizing GNRs to deliver precision heat directly to solid tumors. THT is designed to reduce tumor burden and stimulate immunogenic cell death while minimizing harm to healthy tissue. Sona is advancing THT through clinical trials for solid cancers, including melanoma. Furthermore, the company manufactures and supplies its patented, CTAB-free gold nanoparticles (nanorods and nanospheres) for integration into advanced materials science and medical diagnostic applications, such as lateral flow assays.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2025-10-17 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 85% confidence The document is a NI 52-109FV2 Venture Issuer Basic Certificate signed by the CFO certifying the interim filings (financial statements and MD&A) for the period ended July 31, 2025. It is not the interim report itself (no financials or MD&A content), nor an announcement of its release, but a standalone regulatory certificate required by securities legislation. This does not fit any specific category like IR (which would include the full interim report) or RPA (which would announce a report publication). It is best classified as a general regulatory filing (fallback category).
2025-09-29 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 82% confidence The document is a Form 52-109FV2 “Venture Issuer Basic Certificate” certifying the interim filings (interim financial statements and interim MD&A) under Canadian NI 52-109. It is not the interim report itself, nor is it a short notification announcing publication of a separate report. Instead, it is a standalone regulatory compliance filing (a certificate under securities legislation). No specific category covers NI 52-109 certificates, so it falls under the fallback “Regulatory Filings (RNS)” category.
2025-09-29 English
Interim MD&A - English.pdf
Regulatory Filings
2025-09-29 English
Interim financial statements/report – English.pdf
Regulatory Filings
2025-09-29 English
News release - English.pdf
Regulatory Filings
2025-08-25 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.